Literature DB >> 26837427

Estimating the Effect of Health Insurance on Personal Prescription Drug Importation.

Andrew R Zullo1, Chanelle J Howe1, Omar Galárraga1.   

Abstract

Personal prescription drug importation occurs in the United States because of the high cost of U.S. medicines and lower cost of foreign equivalents. Importation carries a risk of exposure to counterfeit (i.e., falsified, fraudulent), adulterated, and substandard drugs. Inadequate health insurance may increase the risk of importation. We use inverse probability weighted marginal structural models and data on 87,494 individuals from the 2011-2013 National Health Interview Survey to estimate the marginal association between no health insurance and importation within U.S. subpopulations. The marginal prevalence difference [95% confidence limits] for those without (prevalence = 0.031) versus those with health insurance was 0.016 [0.011, 0.021]. The prevalence difference was higher among persons who were Hispanic, born in Latin America, Russia, or Europe, traveled to developing countries, and did not use the Internet to fill prescriptions or to find health information. Health insurance coverage may effectively reduce importation, especially among particular subpopulations.

Entities:  

Keywords:  counterfeit drugs; drug importation; health insurance; health services accessibility; prescription drugs

Mesh:

Substances:

Year:  2016        PMID: 26837427      PMCID: PMC4970983          DOI: 10.1177/1077558716629039

Source DB:  PubMed          Journal:  Med Care Res Rev        ISSN: 1077-5587            Impact factor:   3.929


  44 in total

1.  Marginal structural models as a tool for standardization.

Authors:  Tosiya Sato; Yutaka Matsuyama
Journal:  Epidemiology       Date:  2003-11       Impact factor: 4.822

2.  Quality safeguards and regulation of online pharmacies.

Authors:  Benito Arruñada
Journal:  Health Econ       Date:  2004-04       Impact factor: 3.046

3.  Testing and estimating model-adjusted effect-measure modification using marginal structural models and complex survey data.

Authors:  Babette A Brumback; Erin D Bouldin; Hao W Zheng; Michael B Cannell; Elena M Andresen
Journal:  Am J Epidemiol       Date:  2010-08-26       Impact factor: 4.897

4.  Fade to black: importation and counterfeit drugs.

Authors:  Bryan A Liang
Journal:  Am J Law Med       Date:  2006

5.  New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US.

Authors:  Michael McCarthy
Journal:  BMJ       Date:  2015-04-17

6.  Regulatory underpinnings of Global Health security: FDA's roles in preventing, detecting, and responding to global health threats.

Authors:  Brooke Courtney; Katherine C Bond; Carmen Maher
Journal:  Biosecur Bioterror       Date:  2014 Sep-Oct

7.  Confounding: essence and detection.

Authors:  O S Miettinen; E F Cook
Journal:  Am J Epidemiol       Date:  1981-10       Impact factor: 4.897

8.  Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.

Authors:  Becky A Briesacher; Yanfang Zhao; Jeanne M Madden; Fang Zhang; Alyce S Adams; Jennifer Tjia; Dennis Ross-Degnan; Jerry H Gurwitz; Stephen B Soumerai
Journal:  Med Care       Date:  2011-09       Impact factor: 2.983

9.  Public and private health insurance: stacking up the costs.

Authors:  Leighton Ku; Matthew Broaddus
Journal:  Health Aff (Millwood)       Date:  2008-06-24       Impact factor: 6.301

10.  Investigating the relationship between neighborhood poverty and mortality risk: a marginal structural modeling approach.

Authors:  D Phuong Do; Lu Wang; Michael R Elliott
Journal:  Soc Sci Med       Date:  2013-03-14       Impact factor: 4.634

View more
  1 in total

1.  Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.

Authors:  Mark N Sorial; Justin P Huynh; Christopher G Azzoli; Justin C Liauw; Robert D Brunault; Christine M Collins; Andrew R Zullo
Journal:  Eur J Cancer       Date:  2021-01-08       Impact factor: 9.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.